Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Quick Summary:

"There continues to be an unmet need for patients with obstructive and non-obstructive HCM, and we are excited to be part of the ongoing CIRRUS-HCM trial evaluating a novel treatment," commented Anjali T.Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Associate Professor of Medicine, University of Pennsylvania and CIRRUS-HCM Investigator.

The news is important because hypertrophic cardiomyopathy or HCM for short, is the leading cause of sudden cardiac-related death in people under 35. 

HCM is a genetic disease causing thickening in the heart muscle, an industry worth more than $1.25 billion today and growing.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: MarketBeat

Category: InvestingBusiness

Markets: United States

Topics: Biotech Analyst Ratings Contributors IPOs Markets Mid Cap Insider Trades Price Target Short Sellers EWTX General Trading Ideas Health Care News

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-09-25 @ 15:50:05 (1 days ago)

News Timezone: GMT +8:00

News Source URL: benzinga.com

Language: English

Article Length: 684 words

Reading Time: 4 minutes read

Sentences: 32 lines

Sentence Length: 22 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Benzinga

News ID: 22708689

View Article Analysis

About Benzinga

Main Topics: InvestingBusiness

Official Website: benzinga.com

Year Established: 2010

Headquarters: United States

News Last Updated: 1 days ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #54

Publisher Details

Frequently Asked Questions